, and the 36-month beta value for EYPT is at 1.15. Analysts have varying views on the stock, with 7 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The average price suggested by analysts for EYPT is $31.75, which is $25.21 above the current market price. The public float for EYPT is 30.42M, and currently, shorts hold a 14.00% of that float. The average trading volume for EYPT on June 19, 2023 was 898.62K shares.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it’s about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
EYPT) stock’s latest price update
The stock of EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT) has decreased by -3.68 when compared to last closing price of 6.79.Despite this, the company has seen a gain of 8.10% in its stock price over the last five trading days.
EYPT’s Market Performance
EYPT’s stock has risen by 8.10% in the past week, with a monthly rise of 2.03% and a quarterly rise of 178.30%. The volatility ratio for the week is 7.26% while the volatility levels for the last 30 days are 7.94% for EyePoint Pharmaceuticals Inc. The simple moving average for the last 20 days is 3.92% for EYPT’s stock, with a simple moving average of 31.21% for the last 200 days.
Analysts’ Opinion of EYPT
Many brokerage firms have already submitted their reports for EYPT stocks, with Robert W. Baird repeating the rating for EYPT by listing it as a “Outperform.” The predicted price for EYPT in the upcoming period, according to Robert W. Baird is $33 based on the research report published on April 21st of the current year 2023.
EYPT Trading at 9.10% from the 50-Day Moving Average
After a stumble in the market that brought EYPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -42.83% of loss for the given period.
Volatility was left at 7.94%, however, over the last 30 days, the volatility rate increased by 7.26%, as shares surge +6.69% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +116.20% upper at present.
During the last 5 trading sessions, EYPT rose by +8.10%, which changed the moving average for the period of 200-days by -34.14% in comparison to the 20-day moving average, which settled at $6.31. In addition, EyePoint Pharmaceuticals Inc. saw 86.86% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EYPT starting from Liu Ye, who sale 1 shares at the price of $6.00 back on May 30. After this action, Liu Ye now owns 3,010,721 shares of EyePoint Pharmaceuticals Inc., valued at $6 using the latest closing price.
Stock Fundamentals for EYPT
Current profitability levels for the company are sitting at:
- -190.65 for the present operating margin
- +74.94 for the gross margin
The net margin for EyePoint Pharmaceuticals Inc. stands at -246.97. The total capital return value is set at -43.10, while invested capital returns managed to touch -57.69. Equity return is now at value -88.60, with -51.90 for asset returns.
Based on EyePoint Pharmaceuticals Inc. (EYPT), the company’s capital structure generated 48.09 points at debt to equity in total, while total debt to capital is 32.48. Total debt to assets is 25.70, with long-term debt to equity ratio resting at 36.62. Finally, the long-term debt to capital ratio is 24.73.
When we switch over and look at the enterprise to sales, we see a ratio of 3.38, with the company’s debt to enterprise value settled at 1.43. The receivables turnover for the company is 2.45 and the total asset turnover is 0.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.00.
Conclusion
In conclusion, EyePoint Pharmaceuticals Inc. (EYPT) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.